Sirolimus for corneal dystrophies, hereditary

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 1 May 2019: Trial registered, NCT03933904
  2. 25 Sep 2019: Trial started, NCT03933904

The trials

NCT03933904: Sirolimus in Previously Treated Idiopathic Multicentric Castleman Disease

State
Under way
Phase
Phase 2
People
7 taking part
Started
25 Sep 2019
Primary completion
30 Jun 2024
Arms
Sirolimus
Results
Posted on the registry
  1. 1 May 2019: Trial registered
  2. 25 Sep 2019: Trial started
  3. 8 Aug 2025: Trial results posted

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Also known as Fyarro, Hyftor, Rapalimus, Rapamune, Scomara, Sirolimus (SIR).

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.